Оптимизация купирования приступов мигрени

На состоявшемся под эгидой межрегиональной общественной организации «Российское общество по изучению головной боли» в Москве 24 декабря 2022 г. междисциплинарном Совете экспертов в области головной боли обсуждались ключевые проблемы эффективного лечения приступа мигрени и возможности специфического препарата Капориза® (ризатриптан). Несмотря на разработанность стратегий купирования приступов мигрени и эффективность триптанов как препаратов первой линии, выбор конкретного препарата в соответствии с индивидуальным клиническим профилем пациента является затруднительным ввиду существования препаратов в разнообразных формах (стандартные таблетки, пероральные диспергируемые формы, инъекции, назальные спреи, ректальные суппозитории). Ризатриптан в форме орально диспергируемой таблетки (ОДТ) характеризуется целым рядом преимуществ: высокой биодоступностью, быстрым началом действия, а также удобством применения. Поэтому препарат Капориза® (ризатриптан ОДТ) может быть рекомендован в качестве приоритетной терапии всем пациентам с мигренью, предпочитающим форму диспергируемых таблеток, которые испытывают симптомы тошноты и рвоты, а также пациентам, которые имеют опыт недостаточной эффективности и/или плохой переносимости других триптанов. Совет экспертов рекомендует включить ризатриптан в форме OДТ в следующую редакцию клинических рекомендаций по диагностике и лечению мигрени как препарат первой линии с уровнем доказательности А.

1. World Health Organization. Atlas of headache disorders and resources in the world 2011. A collaborative project of World Health Organization and Lifting The Burden. 2011. ISBN: 9789241564212

2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-22. doi: 10.1016/S0140-6736(20)30925-9

3. Steiner TJ, Stovner LJ, Jensen R, et al; Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0

4. Табеева ГР. Головные боли в общеврачебной практике. Терапевтический архив. 2022;94(1):114-21. doi: 10.26442/00403660.2022.01.201325

5. Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia. 2019;39(6):687-710. doi: 10.1177/0333102419828967

6. Silberstein SD, Newman LC, Marmura MJ, et al. Efficacy endpoints in migraine clinical trials: the importance of assessing freedom from pain. Curr Med Res Opin. 2013 Jul;29(7):861-7. doi: 10.1185/03007995.2013.787980. Epub 2013 May 22.

7. Food and Drug Administration. Migraine: developing drugs for acute treatment. Guidance for industry. 2018. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm419465.pdf (accessed 18.07.2018).

8. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499

9. Lipton RB, Buse DC, Adams AM, et al. Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine. J Fam Pract. 2020 Jan/Feb;69(1 Suppl):S1-S7.

10. Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018 Feb 15;97(4):243-51.

11. Hutchinson S, Lipton RB, Ailani J, et al. Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO Study. Mayo Clin Proc. 2020 Apr;95(4):709-18. doi: 10.1016/j.mayocp.2019.11.025

12. Lipton RB, Munjal S, Alam A, et al. Migraine in America Symptoms and Treatment (MAST) Study: Baseline study methods, treatment patterns, and gender differences. Headache. 2018;58(9):1408-26. doi: 10.1111/head.13407

13. Katic BJ, Rajagopalan S, Ho TW, et al. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia. 2011;31(4):488-500. doi: 10.1177/0333102410383058

14. Serrano D, Buse DC, Kori SH, et al. Effects of switching acute treatment on disability in migraine patients using triptans. Headache. 2013;53(9):1415-29. doi: 10.1111/head.12164

15. Lanteri-Minet M, Massiou H, Romatet S, et al. An instrument to assess patient perception of satisfaction with acute migraine treatment (EXPERT Study). Headache. 2011;51:590-601. doi: 10.1111/j.1526-4610.2011.01867.x

16. Bigal ME, Borucho S, Serrano D, et al. The acute treatment of episodic and chronic migraine in the US. Cephalalgia. 2009;29:891-7. doi: 10.1111/j.1468-2982.2008.01819.x

17. Табеева ГР, Кацарава З, Амелин АВ и др. Новое в осознании бремени мигрени: семантический анализ голоса российских пациентов – пользователей Web 2.0. Неврология, нейропсихиатрия, психосоматика. 2021;13(6):73-84. doi: 10.14412/2074-2711-2021-6-73-84

18. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal populationbased study. Headache. 2008;48(8):1157-68. doi: 10.1111/j.1526-4610.2008.01217.x

19. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi: 10.1177/0333102417738202

20. Ailani J, Burch RC, Robbins MS on behalf of the Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39. doi: 10.1111/head.14153. Epub 2021 Jun 23.

21. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology. 2000;55(6):754-62. doi: 10.1212/wnl.55.6.754

22. Табеева ГР. Специфическое лечение мигрени: история одного триптана. Журнал неврологии и психиатрии им. С.С. Корсакова. 2007;(5):75-8.

23. Migraine: developing drugs for acute treatment [Internet]. Food and Drug Administration; 2018. Available from: https://www.fda.gov/regulatoryinformation/search-fdaguidancedocuments/migraine-developingdrugs-acute-treatment (accessed 16.01.2020).

24. Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: A systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221-35. doi: 10.1111/head.12601

25. Cutrer FM, Goadsby PJ, Ferrari MD, et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). Clin Ther. 2004 Sep;26(9):1533-45. doi: 10.1016/j.clinthera.2004.09.011

26. Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022 Oct 12;23(1):133. doi: 10.1186/s10194-022-01502-z

27. Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. J Pain Res. 2018;11:2221-7. doi: 10.2147/JPR.S152216

28. Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478-88. doi: 10.1177/0333102414547138

29. Silberstein SD. Migraine symptoms: results of a survey of self reported migraineurs. Headache. 1995;35:38. doi: 10.1111/j.1526-4610.1995.hed3507387.x

30. Dahlof CGH, Hargreaves RJ. Pathophysiology and pharmacology of migraine: is there a place for antiemetics in future treatment strategies. Cephalalgia. 1998;18:593-604. doi: 10.1046/j.1468-2982.1998.1809593.x

31. Schurks M, Buring JE, Kurth T. Migraine, migraine features, and cardiovascular disease. Headache. 2010;50:1031-40. doi: 10.1111/j.1526-4610.2009.01609.x

32. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016 Aug;12(8):455-64. doi: 10.1038/nrneurol.2016.93

33. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39 Suppl.2:20-6. doi: 10.1046/j.1526-4610.2002.0420s1003.x

34. Aurora SK, Papapetropoulos S, Kori SH, et al. Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications. Cephalalgia. 2013 Apr;33(6):408-15. doi: 10.1177/0333102412473371

35. Masaoka T, Tack J. Gastroparesis: Current concepts and management. Gut Liver. 2009;3:166-73. doi: 10.5009/gnl.2009.3.3.166

36. Waseem S, Moshiree B, Draganov PV. Gastroparesis: Current diagnostic challenges and management considerations. World J Gastroenterol. 2009;15:25-37. doi: 10.5009/gnl.2009.3.3.166

37. Peroutka SJ. Re: A sympathetic view of “2003 Wolff Award: Possible parasympathetic contributions to peripheral and central sensitization during migraine”. Headache. 2004;44:731-32. doi: 10.1111/j.1526-4610.2004.04134_5.x

38. Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: The clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs. 2010;24:929-40. doi: 10.2165/11317540-000000000-00000

39. Volans GN. Absorption of effervescent aspirin during migraine. Br Med J. 1974;4:265-8. doi: 10.1136/bmj.4.5939.265

40. Tokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984;17:67-75. doi: 10.1111/j.1365-2125.1984.tb05001.x

41. Aurora S, Kori S, Barrodale P, et al. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache. 2007;47:1443-6. doi: 10.1111/j.1526-4610.2007.00922.x

42. Thomsen LL, Dixon R, Lassen LH, et al. 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia. 1996;16:270-5. doi: 10.1046/j.1468-2982.1996.1604270.x

43. Krymchantowski AV, Filho PF, Bigal ME. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: A doubleblind, randomized, crossover, placebo-controlled study. Cephalalgia. 2006;26:871-4. doi: 10.1111/j.1468-2982.2006.01136.x

44. Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol. 2012;14:27-35. doi: 10.1007/s11940-011-0150-9

45. Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2000;17(1):61-72.